Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Apimeds Pharmaceuticals US Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Apimeds Pharmaceuticals US Inc 주요 수익원은 Beauty & Wellness이며, 최신 수익 발표에서 수익은 1,001,334,000입니다. 지역별로는 United States이 Apimeds Pharmaceuticals US Inc의 주요 시장이며, 수익은 1,356,750,000입니다.
Apimeds Pharmaceuticals US Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Apimeds Pharmaceuticals US Inc의 순손실은 $0입니다.